Amundi Acquires 1,040,604 Shares of Colgate-Palmolive (NYSE:CL)

Amundi lifted its stake in Colgate-Palmolive (NYSE:CL - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,200,144 shares of the company's stock after acquiring an additional 1,040,604 shares during the period. Amundi owned 1.13% of Colgate-Palmolive worth $806,015,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. D Orazio & Associates Inc. grew its holdings in Colgate-Palmolive by 3.9% in the third quarter. D Orazio & Associates Inc. now owns 2,862 shares of the company's stock worth $297,000 after purchasing an additional 108 shares during the last quarter. Commonwealth Financial Services LLC increased its holdings in shares of Colgate-Palmolive by 4.5% in the fourth quarter. Commonwealth Financial Services LLC now owns 2,716 shares of the company's stock valued at $247,000 after purchasing an additional 118 shares during the period. Lantz Financial LLC lifted its holdings in shares of Colgate-Palmolive by 0.6% during the fourth quarter. Lantz Financial LLC now owns 20,140 shares of the company's stock worth $1,831,000 after purchasing an additional 122 shares during the period. Horizon Kinetics Asset Management LLC increased its holdings in Colgate-Palmolive by 4.2% in the 3rd quarter. Horizon Kinetics Asset Management LLC now owns 3,102 shares of the company's stock worth $322,000 after buying an additional 124 shares during the period. Finally, Pine Haven Investment Counsel Inc raised its position in Colgate-Palmolive by 1.0% during the 4th quarter. Pine Haven Investment Counsel Inc now owns 13,006 shares of the company's stock worth $1,182,000 after buying an additional 130 shares during the last quarter. Institutional investors own 80.41% of the company's stock.

Remove Ads

Colgate-Palmolive Stock Performance

NYSE:CL traded up $0.72 during mid-day trading on Monday, hitting $97.46. The stock had a trading volume of 9,685,052 shares, compared to its average volume of 4,159,632. Colgate-Palmolive has a 52 week low of $85.32 and a 52 week high of $109.30. The company has a current ratio of 0.92, a quick ratio of 0.58 and a debt-to-equity ratio of 13.40. The stock has a market capitalization of $79.09 billion, a price-to-earnings ratio of 27.69, a P/E/G ratio of 4.20 and a beta of 0.40. The company has a 50 day simple moving average of $88.84 and a 200-day simple moving average of $95.11.

Colgate-Palmolive (NYSE:CL - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.01. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. During the same quarter last year, the company posted $0.87 earnings per share. On average, research analysts expect that Colgate-Palmolive will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 14th. Investors of record on Tuesday, January 21st were given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.05%. The ex-dividend date was Tuesday, January 21st. Colgate-Palmolive's payout ratio is presently 56.82%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. JPMorgan Chase & Co. lowered their price objective on Colgate-Palmolive from $103.00 to $97.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. UBS Group cut their target price on Colgate-Palmolive from $104.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, February 3rd. Wells Fargo & Company dropped their price target on shares of Colgate-Palmolive from $92.00 to $83.00 and set an "underweight" rating for the company in a research note on Tuesday, January 7th. Piper Sandler decreased their price target on Colgate-Palmolive from $121.00 to $112.00 and set an "overweight" rating on the stock in a research note on Monday, January 6th. Finally, Stifel Nicolaus lowered their price objective on shares of Colgate-Palmolive from $95.00 to $93.00 and set a "hold" rating for the company in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $101.61.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.